Zumutor Biologics

Zumutor Biologics Inc., founded in 2015 and headquartered in Woburn, MA, USA, is a pioneering company in the field of Immuno-Oncology, specializing in targeted Natural Killer (NK) cell therapeutics. The company operates in the biotechnology sector, focusing on developing novel immunotherapies and monoclonal antibodies to regulate the tumor microenvironment and enhance innate immunity. Zumutor's proprietary Human Antibody platform, INABLR, is the foundation for its first-in-class therapeutic antibodies, which aim to treat multiple solid cancers. The company serves pharmaceutical and biotechnology clients, leveraging its high-diversity human antibody libraries to identify and develop innovative treatments. Zumutor generates revenue through partnerships, licensing agreements, and the commercialization of its proprietary therapies. The company has an ISO 9001:2008 certified laboratory in Bangalore, India, and has attracted significant investment from global advisors and investors.

Keywords: Immuno-Oncology, NK cell therapeutics, monoclonal antibodies, tumor microenvironment, INABLR platform, solid cancers, biotechnology, immunotherapies, antibody engineering, FDA approval.